ES3040765T3 - Compositions comprising hydroxytyrosol and boswellic acid - Google Patents

Compositions comprising hydroxytyrosol and boswellic acid

Info

Publication number
ES3040765T3
ES3040765T3 ES17720995T ES17720995T ES3040765T3 ES 3040765 T3 ES3040765 T3 ES 3040765T3 ES 17720995 T ES17720995 T ES 17720995T ES 17720995 T ES17720995 T ES 17720995T ES 3040765 T3 ES3040765 T3 ES 3040765T3
Authority
ES
Spain
Prior art keywords
hydroxytyrosol
composition
acetyl
boswellic acid
keto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17720995T
Other languages
English (en)
Spanish (es)
Inventor
Todd Henderson
David Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutramax Laboratories Inc
Original Assignee
Nutramax Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutramax Laboratories Inc filed Critical Nutramax Laboratories Inc
Application granted granted Critical
Publication of ES3040765T3 publication Critical patent/ES3040765T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ES17720995T 2016-10-04 2017-04-21 Compositions comprising hydroxytyrosol and boswellic acid Active ES3040765T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662403807P 2016-10-04 2016-10-04
PCT/US2017/028857 WO2018067200A1 (en) 2016-10-04 2017-04-21 Compositions comprising hydroxytyrosol and boswellic acid

Publications (1)

Publication Number Publication Date
ES3040765T3 true ES3040765T3 (en) 2025-11-04

Family

ID=58664857

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17720995T Active ES3040765T3 (en) 2016-10-04 2017-04-21 Compositions comprising hydroxytyrosol and boswellic acid

Country Status (9)

Country Link
US (3) US11241444B2 (https=)
EP (2) EP4623994A3 (https=)
JP (4) JP7079551B2 (https=)
CN (2) CN109789110A (https=)
AU (3) AU2017340126B2 (https=)
CA (1) CA3039233A1 (https=)
ES (1) ES3040765T3 (https=)
PL (1) PL3522874T3 (https=)
WO (1) WO2018067200A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7079551B2 (ja) 2016-10-04 2022-06-02 ニュートラマックス ラボラトリーズ，インコーポレイテッド ヒドロキシチロソールおよびボスウェリン酸を有する組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358542B2 (en) 1999-12-20 2002-03-19 Usana, Inc. Antioxidant compositions extracted from olives and olive by-products
US7713569B2 (en) 2000-09-01 2010-05-11 Creagri, Inc. Hydroxytyrosol-rich composition from olive vegetation water and method of use thereof
JP3820218B2 (ja) 2000-09-01 2006-09-13 クレアグリ， インコーポレイテッド 植物水からヒドロキシチロソール富化組成物を得る方法
CA2474798C (en) 2002-02-13 2012-12-04 Creagri, Inc. Method and composition for treatment of inflammation and aids-associated neurological disorders
US20030199581A1 (en) 2002-03-13 2003-10-23 Seligson Allen L. Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses
EP1582512A1 (en) 2004-03-31 2005-10-05 Cognis IP Management GmbH Process for obtaining hydroxytyrosol from olive leaves extracts
US7625947B2 (en) 2004-06-18 2009-12-01 Laila Nutraceuticals Analogs of 3-O-acetyl-11-keto-β-boswellic acid
WO2006020588A1 (en) * 2004-08-09 2006-02-23 Creagri, Inc. Olive compositions and methods for treating inflammatory conditions
EP2040696B1 (en) * 2006-07-14 2017-01-25 DSM IP Assets B.V. Compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders
WO2008006582A1 (en) 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases
JP2008120716A (ja) 2006-11-10 2008-05-29 Eisai Food Chemical Kk 抗炎症剤
KR101682512B1 (ko) * 2008-09-15 2016-12-05 라일라 뉴트라슈티칼스 보스웰리아 세라타 추출물을 포함하는 상승적인 항-염증 조성물
CN102451428A (zh) * 2010-10-14 2012-05-16 中国中医科学院广安门医院 可用于治疗类风湿关节炎的中药组合物
WO2014085613A1 (en) * 2012-11-30 2014-06-05 Mccord Darlene E Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
US10342802B2 (en) 2016-10-04 2019-07-09 Nutramax Laboratories, Inc. Compositions comprising hydroxytyrosol and boswellic acid
JP7079551B2 (ja) 2016-10-04 2022-06-02 ニュートラマックス ラボラトリーズ，インコーポレイテッド ヒドロキシチロソールおよびボスウェリン酸を有する組成物

Also Published As

Publication number Publication date
CA3039233A1 (en) 2018-04-12
EP3522874B1 (en) 2025-07-02
JP2024166415A (ja) 2024-11-28
JP2023159387A (ja) 2023-10-31
JP7562225B2 (ja) 2024-10-07
JP7341596B2 (ja) 2023-09-11
AU2023203427B2 (en) 2025-02-06
US20220110946A1 (en) 2022-04-14
AU2017340126A1 (en) 2019-04-11
WO2018067200A1 (en) 2018-04-12
US11241444B2 (en) 2022-02-08
CN109789110A (zh) 2019-05-21
US11980624B2 (en) 2024-05-14
JP2022110125A (ja) 2022-07-28
AU2017340126B2 (en) 2023-03-02
JP2019529482A (ja) 2019-10-17
US20200222424A1 (en) 2020-07-16
CN120241745A (zh) 2025-07-04
JP7079551B2 (ja) 2022-06-02
AU2023203427A1 (en) 2023-06-29
EP4623994A3 (en) 2025-11-19
AU2025202875A1 (en) 2025-05-15
US20240285648A1 (en) 2024-08-29
EP3522874A1 (en) 2019-08-14
PL3522874T3 (pl) 2025-10-06
EP4623994A2 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
Ferreira et al. Natural products for the prevention and treatment of oral mucositis—a review
JP5662492B2 (ja) 抗炎症製剤
US10485784B2 (en) Orally administrable compositions compromising avocado/soybean unsaponifiables and lipoic acid and methods of administration
AU2025202875A1 (en) Compositions comprising hydroxytyrosol and boswellic acid
US10722524B2 (en) Compositions comprising hydroxytyrosol and boswellic acid
Falvino et al. Which approach to choose to counteract musculoskeletal aging? A comprehensive review on the multiple effects of exercise
Nwosu et al. Bioactive lead compounds and molecular targets for the development of antiinflammatory drugs
US20160129056A1 (en) Nutraceutical supplement with lactobacillus rhamnosus
US20230248755A1 (en) Compositions for improving joint health
NL2039507B1 (en) Composition containing fish bone powder and plant extract for effective improvement in bone joint health
Amer Could ginger extract be a therapeutic drug for migraine
Manchanda et al. A multicenter, observational, homoeopathic clinical verification study of Cynodon dactylon revealing symptom prevalence in a cohort of 340 patients
Rezaieyazdi et al. Oral intake of purple passion fruit peel extract reduces pain and stiffness and improves physical function in adult patients...
NZ618389B2 (en) Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
ITMI20100318A1 (it) Associazione tra un analgesico ad azione centrale e un antinfiammatorio inibitore selettivo della cicloossigenasi 2 per il trattamento dell'infiammazione e del dolore in campo veterinario